In recent years, there’s been a shift in how we think about psychedelics – from drugs of abuse and recreation, to powerful drugs for treating neuropsychiatric conditions such as depression, addiction, and PTSD.
But there’s still a lot we don't know about how they work, and how we can maximize their therapeutic benefits while minimizing their adverse side effects. So this episode of Journal Club discusses a method for striking that balance, from a paper published in Nature last month, “A non-hallucinogenic psychedelic analogue with therapeutic potential“... which could represent a major step forward in psychedelic medicine.
This episode first appeared on Bio Eats World:
https://a16z.com/2021/01/21/journal-club-safer-psychedelic/
Stay Updated:
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
